Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
282 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ebola Viral Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H1 2016', provides an overview of the Ebola Viral Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebola Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebola Viral Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews pipeline therapeutics for Ebola Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ebola Viral Infections therapeutics and enlists all their major and minor projects - The report assesses Ebola Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ebola Viral Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Ebola Viral Infections Overview 7 Therapeutics Development 8 Ebola Viral Infections - Therapeutics under Development by Companies 10 Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes 14 Ebola Viral Infections - Pipeline Products Glance 15 Ebola Viral Infections - Products under Development by Companies 19 Ebola Viral Infections - Products under Investigation by Universities/Institutes 24 Ebola Viral Infections - Companies Involved in Therapeutics Development 25 Ebola Viral Infections - Therapeutics Assessment 70 Drug Profiles 80 Ebola Viral Infections - Recent Pipeline Updates 207 Ebola Viral Infections - Dormant Projects 255 Ebola Viral Infections - Discontinued Products 259 Ebola Viral Infections - Product Development Milestones 260 Appendix 271
List of Tables
Number of Products under Development for Ebola Viral Infections, H1 2016 18 Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Development, H1 2016 27 Comparative Analysis by Unknown Stage Development, H1 2016 28 Products under Development by Companies, H1 2016 29 Products under Development by Companies, H1 2016 (Contd..1) 30 Products under Development by Companies, H1 2016 (Contd..2) 31 Products under Development by Companies, H1 2016 (Contd..3) 32 Products under Development by Companies, H1 2016 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2016 34 Ebola Viral Infections - Pipeline by Abivax S.A., H1 2016 35 Ebola Viral Infections - Pipeline by AnGes MG, Inc., H1 2016 36 Ebola Viral Infections - Pipeline by ANP Technologies, Inc., H1 2016 37 Ebola Viral Infections - Pipeline by Arno Therapeutics, Inc., H1 2016 38 Ebola Viral Infections - Pipeline by Avipero Limited, H1 2016 39 Ebola Viral Infections - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016 40 Ebola Viral Infections - Pipeline by BioFactura, Inc., H1 2016 41 Ebola Viral Infections - Pipeline by Celgene Corporation, H1 2016 42 Ebola Viral Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 43 Ebola Viral Infections - Pipeline by Enyo Pharma S.A.S., H1 2016 44 Ebola Viral Infections - Pipeline by Etubics Corporation, H1 2016 45 Ebola Viral Infections - Pipeline by GeoVax Labs, Inc., H1 2016 46 Ebola Viral Infections - Pipeline by Gilead Sciences, Inc., H1 2016 47 Ebola Viral Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 48 Ebola Viral Infections - Pipeline by Globavir Biosciences, Inc., H1 2016 49 Ebola Viral Infections - Pipeline by Hemispherx Biopharma, Inc., H1 2016 50 Ebola Viral Infections - Pipeline by Humabs BioMed SA, H1 2016 51 Ebola Viral Infections - Pipeline by Immune Response BioPharma, Inc., H1 2016 52 Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H1 2016 53 Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 54 Ebola Viral Infections - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 55 Ebola Viral Infections - Pipeline by Johnson & Johnson, H1 2016 56 Ebola Viral Infections - Pipeline by Kineta, Inc., H1 2016 57 Ebola Viral Infections - Pipeline by Kymab Limited, H1 2016 58 Ebola Viral Infections - Pipeline by Merck & Co., Inc., H1 2016 59 Ebola Viral Infections - Pipeline by Microbiotix, Inc., H1 2016 60 Ebola Viral Infections - Pipeline by Micropharm Limited, H1 2016 61 Ebola Viral Infections - Pipeline by NanoViricides, Inc., H1 2016 62 Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 63 Ebola Viral Infections - Pipeline by Novavax, Inc., H1 2016 64 Ebola Viral Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016 65 Ebola Viral Infections - Pipeline by Phelix Therapeutics, LLC, H1 2016 66 Ebola Viral Infections - Pipeline by Profectus BioSciences, Inc., H1 2016 67 Ebola Viral Infections - Pipeline by RedHill Biopharma Ltd., H1 2016 68 Ebola Viral Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 69 Ebola Viral Infections - Pipeline by SignPath Pharma Inc, H1 2016 70 Ebola Viral Infections - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 71 Ebola Viral Infections - Pipeline by Sirnaomics, Inc., H1 2016 72 Ebola Viral Infections - Pipeline by Soligenix, Inc., H1 2016 73 Ebola Viral Infections - Pipeline by Taiga Biotechnologies, Inc., H1 2016 74 Ebola Viral Infections - Pipeline by Tamir Biotechnology, Inc., H1 2016 75 Ebola Viral Infections - Pipeline by TGV-Laboratories, H1 2016 76 Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2016 77 Ebola Viral Infections - Pipeline by Vaxeal Holding SA, H1 2016 78 Ebola Viral Infections - Pipeline by XBiotech USA, Inc., H1 2016 79 Assessment by Monotherapy Products, H1 2016 80 Assessment by Combination Products, H1 2016 81 Number of Products by Stage and Target, H1 2016 83 Number of Products by Stage and Mechanism of Action, H1 2016 85 Number of Products by Stage and Route of Administration, H1 2016 87 Number of Products by Stage and Molecule Type, H1 2016 89 Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H1 2016 217 Ebola Viral Infections - Dormant Projects, H1 2016 265 Ebola Viral Infections - Dormant Projects (Contd..1), H1 2016 266 Ebola Viral Infections - Dormant Projects (Contd..2), H1 2016 267 Ebola Viral Infections - Dormant Projects (Contd..3), H1 2016 268 Ebola Viral Infections - Discontinued Products, H1 2016 269
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
